Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study.
Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study.
复制标题
DOI：
10.1177/17455057231190955
复制
发表时间：
2023-01
期刊：
影响因子：
2.4
通讯作者：
Lacourse, Sylvia M.
中科院分区：
文献类型：
--
作者：
Drake, Alison L.;Escudero, Jaclyn N.;Aurelio, Morgan C.;Wetzler, Erica A.;Ellington, Sascha R.;Zapata, Lauren B.;Galang, Romeo R.;Snead, Margaret C.;Yamamoto, Krissy;Salerno, Carol C.;Richardson, Barbra A.;Greninger, Alexander L.;Kachikis, Alisa B.;Englund, Janet A.;Lacourse, Sylvia M.
产前护理提供了独特的机会，以评估严重急性呼吸系统综合征冠状病毒2血清阳性率和抗体反应持续时间后，自然感染在怀孕期间检测;经胎盘抗体转移可能会告知围产期和新生儿的保护。我们估计血清阳性率和持久性抗体自然感染（抗核衣壳免疫球蛋白G）在孕妇中，并评估经胎盘转移效率。我们进行了一项横断面研究来测量严重急性呼吸综合征冠状病毒2型血清阳性率，并进行了一项前瞻性队列研究来纵向测量抗核衣壳免疫球蛋白G反应和母体来源的抗核衣壳抗体的经胎盘转移。我们于2020年12月9日至2021年6月19日在华盛顿的西雅图对孕妇进行了抗核衣壳免疫球蛋白G血清阳性率研究筛查。我们在2020年12月9日至2022年8月9日的前瞻性队列中招募了血清阳性率研究中的抗核衣壳免疫球蛋白G阳性患者，或通过病历确定的逆转录聚合酶链反应阳性或抗原阳性结果。在横断面研究（N = 1284）中，5%（N = 65）的严重急性呼吸综合征冠状病毒2型抗核衣壳免疫球蛋白G检测阳性，包括39例（60%）既往无阳性逆转录聚合酶链反应结果和42例（65%）无症状。在前瞻性队列研究中（共N = 107例; N = 65例来自血清阳性率研究），86例（N = 80%）在妊娠期间具有抗核衣壳免疫球蛋白G阳性结果。在63名有分娩样本和既往抗核衣壳阳性结果的参与者中，29名（46%）分娩时抗核衣壳免疫球蛋白G阴性。剩余的34个抗核衣壳免疫球蛋白G阳性分娩时配对的脐带血，19（56%）有有效的经胎盘抗核衣壳免疫球蛋白G抗体转移。从首次抗核衣壳免疫球蛋白G阳性到低于阳性抗体阈值的中位时间为19周，且既往逆转录聚合酶链反应阳性状态无差异。母体来源的严重急性呼吸综合征冠状病毒2抗体自然感染可能会在分娩前减弱。建议孕妇接种疫苗，以减少严重疾病并保护婴儿。
Antenatal care provides unique opportunities to assess severe acute respiratory syndrome coronavirus 2 seroprevalence and antibody response duration after natural infection detected during pregnancy; transplacental antibody transfer may inform peripartum and neonatal protection. We estimated seroprevalence and durability of antibodies from natural infection (anti-nucleocapsid immunoglobulin G) among pregnant people, and evaluated transplacental transfer efficiency. We conducted a cross-sectional study to measure severe acute respiratory syndrome coronavirus 2 seroprevalence, and a prospective cohort study to longitudinally measure anti-nucleocapsid immunoglobulin G responses and transplacental transfer of maternally derived anti-nucleocapsid antibodies. We screened pregnant people for the seroprevalence study between 9 December 2020 and 19 June 2021 for anti-nucleocapsid immunoglobulin G in Seattle, Washington. We enrolled anti-nucleocapsid immunoglobulin G positive people from the seroprevalence study or identified through medical records with positive reverse transcription polymerase chain reaction or antigen positive results in a prospective cohort between 9 December 2020 and 9 August 2022. In the cross-sectional study (N = 1284), 5% (N = 65) tested severe acute respiratory syndrome coronavirus 2 anti-nucleocapsid immunoglobulin G positive, including 39 (60%) without prior positive reverse transcription polymerase chain reaction results and 42 (65%) without symptoms. In the prospective cohort study (N = 107 total; N = 65 from the seroprevalence study), 86 (N = 80%) had anti-nucleocapsid immunoglobulin G positive results during pregnancy. Among 63 participants with delivery samples and prior anti-nucleocapsid positive results, 29 (46%) were anti-nucleocapsid immunoglobulin G negative by delivery. Of 34 remaining anti-nucleocapsid immunoglobulin G positive at delivery with paired cord blood, 19 (56%) had efficient transplacental anti-nucleocapsid immunoglobulin G antibody transfer. Median time from first anti-nucleocapsid immunoglobulin G positive to below positive antibody threshold was 19 weeks and did not differ by prior positive reverse transcription polymerase chain reaction status. Maternally derived severe acute respiratory syndrome coronavirus 2 antibodies to natural infection may wane before delivery. Vaccines are recommended for pregnant persons to reduce severe illness and confer protection to infants.
登录
查看更多内容
DOI：
10.1016/j.jcv.2021.104765
发表时间：
2021-03
期刊：
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
影响因子：
--
作者：
Van Elslande J;Oyaert M;Ailliet S;Van Ranst M;Lorent N;Vande Weygaerde Y;André E;Lagrou K;Vandendriessche S;Vermeersch P
通讯作者：
Vermeersch P
影响因子：
13.8
作者：
Edlow AG;Li JZ;Collier AY;Atyeo C;James KE;Boatin AA;Gray KJ;Bordt EA;Shook LL;Yonker LM;Fasano A;Diouf K;Croul N;Devane S;Yockey LJ;Lima R;Shui J;Matute JD;Lerou PH;Akinwunmi BO;Schmidt A;Feldman J;Hauser BM;Caradonna TM;De la Flor D;D'Avino P;Regan J;Corry H;Coxen K;Fajnzylber J;Pepin D;Seaman MS;Barouch DH;Walker BD;Yu XG;Kaimal AJ;Roberts DJ;Alter G
通讯作者：
Alter G
影响因子：
3.7
作者：
Ochola R;Sande C;Fegan G;Scott PD;Medley GF;Cane PA;Nokes DJ
通讯作者：
Nokes DJ
影响因子：
12.7
作者：
Falsey, Ann R.;Singh, Harjot K.;Walsh, Edward E.
通讯作者：
Walsh, Edward E.
影响因子：
2
作者：
Buckley, Ayisha;Mills, Ariana;Bianco, Angela
通讯作者：
Bianco, Angela